|Bid||33.61 x N/A|
|Ask||33.84 x N/A|
|Day's range||33.41 - 33.98|
|52-week range||33.26 - 42.32|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Blue-chip companies Unilever, AstraZeneca and British American Tobacco today lead a busy session for end-of-year corporate earnings. AstraZeneca boss Pascal Soriot reported a 25% rise in revenues to $44.3 billion (£36.6 billion) and said he expects to see another year of double-digit revenue growth in 2023. Unilever profits topped 8 billion euros (£7.1 billion) last year, partly thanks to higher prices for its consumer goods brands including Hellman’s, Domestos and Ben & Jerry’s. It warned that while inflation is tempering, there are most cost increases to come this year.
The division is now expected to be profitable by 2024, but shares declined in early trading
British American Tobacco (BAT) reported full-year sales growth of between 2% and 4% after an increase in consumer use of its e-cigarette range.